Eupraxia Pharmaceuticals Inc. (EPRX.TO)
| Previous Close | 3.7200 |
| Open | 3.7600 |
| Bid | 3.9000 x N/A |
| Ask | 3.9500 x N/A |
| Day's Range | 3.7600 - 3.9800 |
| 52 Week Range | 3.4400 - 9.1000 |
| Volume | |
| Avg. Volume | 66,946 |
| Market Cap | 140.353M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1700 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.45 |
CNW GroupEupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program. The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano
- Baystreet
Stocks in play: Eupraxia Pharmaceuticals Inc.
Announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society ...
CNW GroupEupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.
